Age Related Macular Degeneration - Pipeline Review, H2 2015

Date: December 30, 2015
Pages: 580
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AB7CC0F0839EN
Leaflet:

Download PDF Leaflet

Age Related Macular Degeneration - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Age Related Macular Degeneration - Pipeline Review, H2 2015’, provides an overview of the Age Related Macular Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Age Related Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Age Related Macular Degeneration Overview
Therapeutics Development
Age Related Macular Degeneration - Therapeutics under Development by Companies
Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
Age Related Macular Degeneration - Pipeline Products Glance
Age Related Macular Degeneration - Products under Development by Companies
Age Related Macular Degeneration - Products under Investigation by Universities/Institutes
Age Related Macular Degeneration - Companies Involved in Therapeutics Development
Age Related Macular Degeneration - Therapeutics Assessment
Drug Profiles
Age Related Macular Degeneration - Recent Pipeline Updates
Age Related Macular Degeneration - Dormant Projects
Age Related Macular Degeneration - Discontinued Products
Age Related Macular Degeneration - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Age Related Macular Degeneration, H2 2015
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Investigation by Universities/Institutes, H2 2015
Age Related Macular Degeneration - Pipeline by AC Immune SA, H2 2015
Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Aciont Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Acucela Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Allergan Plc, H2 2015
Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H2 2015
Age Related Macular Degeneration - Pipeline by Amakem NV, H2 2015
Age Related Macular Degeneration - Pipeline by Amarna Therapeutics B.V., H2 2015
Age Related Macular Degeneration - Pipeline by Amyndas Pharmaceuticals LLC, H2 2015
Age Related Macular Degeneration - Pipeline by AngioGenex, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Apexigen, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2015
Age Related Macular Degeneration - Pipeline by BIOCAD, H2 2015
Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by BioMAS Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Age Related Macular Degeneration - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Age Related Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Charlesson LLC., H2 2015
Age Related Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Age Related Macular Degeneration - Pipeline by Circadian Technologies Limited, H2 2015
Age Related Macular Degeneration - Pipeline by Clanotech AB, H2 2015
Age Related Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Company, H2 2015
Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Critical Pharmaceuticals Limited, H2 2015
Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Age Related Macular Degeneration - Pipeline by Digna Biotech, S.L., H2 2015
Age Related Macular Degeneration - Pipeline by Dong-A Socio Group, H2 2015
Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Exonate Limited, H2 2015
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Formycon AG, H2 2015
Age Related Macular Degeneration - Pipeline by Gene Signal International SA, H2 2015
Age Related Macular Degeneration - Pipeline by Genentech, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2015
Age Related Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2015
Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Age Related Macular Degeneration - Pipeline by GTx, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co., Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by IMMD Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Innovent Biologics, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by International Stem Cell Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H2 2015
Age Related Macular Degeneration - Pipeline by Kadmon Corporation, LLC, H2 2015
Age Related Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Lead Discovery Center GmbH, H2 2015
Age Related Macular Degeneration - Pipeline by LeadArtis S.L., H2 2015
Age Related Macular Degeneration - Pipeline by Mabion SA, H2 2015
Age Related Macular Degeneration - Pipeline by MacuCLEAR, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015
Age Related Macular Degeneration - Pipeline by Mitotech S.A., H2 2015
Age Related Macular Degeneration - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Neovacs SA, H2 2015
Age Related Macular Degeneration - Pipeline by Neumedicines Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H2 2015
Age Related Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Novartis AG, H2 2015
Age Related Macular Degeneration - Pipeline by Ocata Therapeutics, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Omeros Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by Ophthotech Corp., H2 2015
Age Related Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2015
Age Related Macular Degeneration - Pipeline by PanOptica, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Pfenex Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Pfizer Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Promedior, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Protelica Incorporated, H2 2015
Age Related Macular Degeneration - Pipeline by pSivida Corp., H2 2015
Age Related Macular Degeneration - Pipeline by QLT Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Ra Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by RegenxBio Inc., H2 2015
Age Related Macular Degeneration - Pipeline by RestorGenex Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by Ribomic Inc., H2 2015
Age Related Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by SanBio, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Age Related Macular Degeneration - Pipeline by Sirnaomics, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by StemCells, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by U.S. Stem Cell, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by VasGene Therapeutics, Inc., H2 2015
Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corporation, H2 2015
Age Related Macular Degeneration - Pipeline by Xbrane Bioscience AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Age Related Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2015
Age Related Macular Degeneration - Dormant Projects, H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..1), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..2), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..3), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..4), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..5), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..6), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..7), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..8), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..9), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..10), H2 2015
Age Related Macular Degeneration - Dormant Projects (Contd..11), H2 2015
Age Related Macular Degeneration - Discontinued Products, H2 2015
Age Related Macular Degeneration - Discontinued Products (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Age Related Macular Degeneration, H2 2015
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AC Immune SA
Achillion Pharmaceuticals, Inc.
Aciont Inc.
Acucela Inc.
Aerie Pharmaceuticals, Inc.
Aerpio Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.
Alimera Sciences, Inc.
Alkeus Pharmaceuticals, Inc.
Allergan Plc
Allinky Biopharma
Amakem NV
Amarna Therapeutics B.V.
Amyndas Pharmaceuticals LLC
AngioGenex, Inc.
Apellis Pharmaceuticals, Inc.
Apexigen, Inc.
Applied Genetic Technologies Corporation
Avalanche Biotechnologies, Inc.
Benitec Biopharma Limited
BIOCAD
Biokine Therapeutics Ltd.
BioMAS Ltd.
Boehringer Ingelheim GmbH
Caladrius Biosciences, Inc.
Catalyst Biosciences, Inc.
Cell Cure Neurosciences, Ltd.
Charlesson LLC.
Chong Kun Dang Pharmaceutical Corp.
Circadian Technologies Limited
Clanotech AB
Clearside BioMedical, Inc.
Colby Pharmaceutical Company
Crinetics Pharmaceuticals, Inc.
Critical Pharmaceuticals Limited
Daiichi Sankyo Company, Limited
Digna Biotech, S.L.
Dong-A Socio Group
Eleven Biotherapeutics Inc.
Exonate Limited
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Formycon AG
Gene Signal International SA
Genentech, Inc.
GenSight Biologics SA
GlaxoSmithKline Plc
Grupo Ferrer Internacional, S.A.
GTx, Inc.
HanAll Biopharma Co., Ltd.
Huabo Biopharm Co., Ltd.
iCo Therapeutics Inc.
Icon Bioscience, Inc.
Iconic Therapeutics, Inc.
IMMD Inc.
Innovent Biologics, Inc.
Intellect Neurosciences, Inc.
International Stem Cell Corporation
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kala Pharmaceuticals, Inc.
Lead Discovery Center GmbH
LeadArtis S.L.
Mabion SA
MacuCLEAR, Inc.
Merz Pharma GmbH & Co. KgaA
Mitotech S.A.
Mitsubishi Tanabe Pharma Corporation
Navigen Pharmaceuticals, Inc.
Neovacs SA
Neumedicines Inc.
Neuroptis Biotech
Neurotech Pharmaceuticals, Inc.
Novartis AG
Ocata Therapeutics, Inc.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Omeros Corporation
Ophthotech Corp.
Orphagen Pharmaceuticals, Inc.
Oxford BioMedica Plc
PanOptica, Inc.
Pfenex Inc.
Pfizer Inc.
Promedior, Inc.
Protelica Incorporated
pSivida Corp.
QLT Inc.
Quark Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
RegenxBio Inc.
RestorGenex Corporation
Ribomic Inc.
RXi Pharmaceuticals Corporation
SanBio, Inc.
Santen Pharmaceutical Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
SciFluor Life Sciences, LLC
Sirnaomics, Inc.
StemCells, Inc.
Sucampo Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Compan
TRACON Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc.
Tyrogenex, Inc.
U.S. Stem Cell, Inc.
VasGene Therapeutics, Inc.
Wellstat Ophthalmics Corporation
Xbrane Bioscience AB
Skip to top


Ask Your Question

Age Related Macular Degeneration - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: